MK-1248 / Merck (MSD) - LARVOL DELTA

First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. (ASCO 2018) - P1; "MK-1248 at the dose up to 170 mg as monotherapy and 60 mg in combination with pembrolizumab was well tolerated with no dose limiting toxicities or treatment-related deaths. Responses were observed when MK-1248 was administered in combination with pembrolizumab."

Clinical • Combination therapy • Monotherapy • P1 data • Colorectal Cancer • Melanoma • Renal Cell Carcinoma

First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. (PubMed, Cancer) - P1 | "MK-1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment-related deaths. Combination therapy provided limited antitumor responses."

Clinical • Journal • Monotherapy • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Melanoma • Renal Cell Carcinoma • Solid Tumor

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial primary completion date: Aug 2017 ➔ Nov 2017

Trial primary completion date • Biosimilar • Oncology